Aldosterone Synthase Inhibitors Pipeline Research Report 2021: Comprehensive Insights About 4+ Companies and 4+ Pipeline Drugs - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Aldosterone Synthase Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

This "Aldosterone synthase inhibitors - Pipeline Insight, 2021" report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Aldosterone synthase inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products.

It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

The companies and academics are working to assess challenges and seek opportunities that could influence Aldosterone synthase inhibitors R&D. The therapies under development are focused on novel approaches for Aldosterone synthase inhibitors.

Aldosterone synthase inhibitors Emerging Drugs Chapters

This segment of the Aldosterone synthase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Aldosterone synthase inhibitors Emerging Drugs

MLS 101: Mineralys Therapeutics

MLS 101 is a highly selective and potent aldosterone synthase inhibitor, that is being investigated for the treatment of hypertension. It selectively inhibits CYP11B2 pathway responsible for the synthesis of aldosterone and has no untoward effect of blocking the mineralocorticoid receptors, thereby significantly reducing plasma aldosterone levels without affecting other hormones like cortisol. Currently, it is in Phase II stage of clinical trial evaluation to treat hypertension.

DP13: Damian Pharma

An aldosterone synthase inhibitor, DP13 is a first-of-its-kind treatment for PA that medically targets the cause of the disease. DAMIAN successfully completed its Phase I Clinical Trial evaluating the pharmacological properties of DP13 in healthy volunteers. The safety and efficacy of DP13 is currently being investigated across Europe in patients with Primary Aldosteronism (PA) in a Phase II Trial.

Aldosterone synthase inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Aldosterone synthase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Aldosterone synthase inhibitors

There are approx. 4+ key companies which are developing the Aldosterone synthase inhibitors. The companies which have their Aldosterone synthase inhibitors drug candidates in the most advanced stage, i.e. Phase II include, Mineralys Therapeutics.

Key Questions Answered

• How many companies are developing Aldosterone synthase inhibitors drugs?
• How many Aldosterone synthase inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Aldosterone synthase inhibitors?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Aldosterone synthase inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Aldosterone synthase inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Mineralys Therapeutics
• DAMIAN PHARMA AG
• CinCor Pharma
• Laekna Therapeutics
• Angion Biomedica
• PhaseBio Pharmaceuticals

Key Products

• MLS 101
• DP13
• CIN 107
• LAE 001
• PB 6440

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/os3tl4